Pyxis Oncology Insiders Recover Some Losses, Which Stand At US$65k

Some of the losses seen by insiders who purchased US$174.4k worth of Pyxis Oncology, Inc. (NASDAQ:PYXS) shares over the past year were recovered after the stock increased by 16% over the past week. However, total losses seen by insiders are still US$65k since the time of purchase.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

The Last 12 Months Of Insider Transactions At Pyxis Oncology

In the last twelve months, the biggest single purchase by an insider was when insider Pamela Connealy bought US$174k worth of shares at a price of US$2.00 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$1.23). It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was Pamela Connealy.

The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

Check out our latest analysis for Pyxis Oncology

Pyxis Oncology is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership Of Pyxis Oncology

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Insiders own 6.3% of Pyxis Oncology shares, worth about US$4.8m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.

So What Does This Data Suggest About Pyxis Oncology Insiders?

It doesn't really mean much that no insider has traded Pyxis Oncology shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Pyxis Oncology stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Pyxis Oncology. In terms of investment risks, we've identified 3 warning signs with Pyxis Oncology and understanding them should be part of your investment process.

But note: Pyxis Oncology may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.